Sareum Holdings PLC
RYH0
Company Profile
Business description
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
Contact
Langford Arch, London Road
Unit 2a, Pampisford
CambridgeCambridgeshireCB22 3FX
GBRT: +44 1223497700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
What did Morningstar subscribers buy and sell during February?
How the most traded shares stack up against our analysts views.
stocks
Paying more for new customers is a troubling sign for ASX share
Shares fall close to 18% after reporting higher marketing expenses.
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,164.90 | 7.20 | 0.08% |
| CAC 40 | 8,186.35 | 18.62 | 0.23% |
| DAX 40 | 24,276.81 | 71.45 | 0.30% |
| Dow JONES (US) | 48,501.27 | 403.51 | -0.83% |
| FTSE 100 | 10,594.72 | 110.59 | 1.05% |
| HKSE | 25,321.34 | 446.74 | -1.73% |
| NASDAQ | 22,807.48 | 290.79 | 1.29% |
| Nikkei 225 | 55,278.06 | 1,000.99 | -1.78% |
| NZX 50 Index | 13,617.89 | 2.32 | -0.02% |
| S&P 500 | 6,816.63 | 64.99 | -0.94% |
| S&P/ASX 200 | 8,940.30 | 3.30 | 0.04% |
| SSE Composite Index | 4,108.57 | 26.09 | 0.64% |